2,665 results on '"Keating, Michael J."'
Search Results
152. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
153. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
154. Customized Oligonucleotide Array-Based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia
155. Parliamentary Behaviour as a Test of Scottish Integration into the United Kingdom
156. Use of Trimethoprim-Sulfamethoxazole for Treatment of Infections in Patients with Cancer
157. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells
158. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism
159. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells
160. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
161. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
162. What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?
163. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
164. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
165. Use of IGHV3–21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post–germinal center leukemogenic selection
166. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3
167. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
168. Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia
169. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
170. Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival
171. Richter’s transformation in chronic lymphocytic leukemia
172. New aspects of the treatment of chronic lymphocytic leukemia
173. Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007
174. Identification and Validation of Biomarkers of IgV H Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology
175. Chemoimmunotherapy of chronic lymphocytic leukemia
176. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
177. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism
178. Refractory Chronic Lymphocytic Leukemia: Prognosis and Treatment Options
179. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity
180. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
181. Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study
182. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia
183. Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib
184. The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL
185. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia
186. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
187. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
188. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia
189. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
190. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center
191. Approach to frontline therapy in elderly chronic lymphocytic leukemia patients
192. Characterization of 4 mantle cell lymphoma cell lines: establishment of an in vitro study model
193. Eradication of minimal residual disease in hairy cell leukemia
194. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
195. Monoclonal antibody combinations in CLL: evolving strategies
196. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL
197. Predicting survival in chronic lymphocytic leukemia
198. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
199. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia†‡
200. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.